The company said March 17 it is the first U.S. commercial lab to offer the test, which was developed by Immundiagnostik. It detects gluten in a patient’s stool sample.
“Having the ability to confirm and measure unintended gluten exposure gives patients more control over their diets and their health,” Celiac Disease Foundation CEO Marilyn Geller said in the news release. “Labcorp is the first clinical reference lab in the United States to offer a test that utilizes stool samples to directly quantify the disease-triggering source. This new option opens the door for more people across the country to better manage their celiac disease or [non-celiac gluten sensitivity].”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
